Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Plus Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REYOBIQ PRODUCED A CLINICAL BENEFIT RATE OF OVER 75% IN 3 CLINICALLY RELEVANT OUTCOME MEASURES RNA SEQUENCING AND CIRCULATING TUMOR CELL REDUCTION CONSISTENT WITH TUMOR CELL DEATH NO DOSE LIMITING TOXICITIES WERE OBSERVED WITH AN OVERALL FAVORABLE SAFETY PROFILE HOUSTON, AUG. 18, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCES POSITIVE DATA FROM THE RESPECT-LM PHASE 1 SINGLE DOSE ESCALATION TRIAL PRESENTED AT THE PODIUM AT THE SNO/ASCO CNS METASTASES CONFERENCE IN BALTIMORE, MD. THE DATA DEMONSTRATED TREATMENT OF LEPTOMENINGEAL METASTASES (LM) WITH REYOBIQ IS FEASIBLE, HAS A MANAGEABLE SAFETY PROFILE, AND SHOWS A PROMISING EFFICACY SIGNAL.

PLUS THERAPEUTICS PRESENTS POSITIVE RESPECT-LM CLINICAL TRIAL RESULTS OF REYOBIQ IN LEPTOMENINGEAL METASTASES

HOUSTON, AUG. 15, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (PLUS OR THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCED IT REPORTED STOCKHOLDERS' EQUITY OF $3MILLION AND THEREFORE SATISFIED NASDAQ LISTING RULE 5550(B)(1) (THE EQUITY RULE), AS OF JUNE30, 2025. THE EQUITY RULE REQUIRES LISTED COMPANIES TO MAINTAIN A MINIMUM OF $2.5MILLION IN STOCKHOLDERS' EQUITY.

PLUS THERAPEUTICS REPORTS STOCKHOLDERS' EQUITYIN EXCESS OF $2.5 MILLION IN COMPLIANCE WITH NASDAQ EQUITY REQUIREMENTS

ANNOUNCED CNSIDE CSF ASSAY PLATFORM LAUNCH TIMELINE INITIATED THE REYOBIQ DOSE OPTIMIZATION TRIAL FOR PATIENTS WITH LEPTOMENINGEAL METASTASES HOUSTON, AUG. 14, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ: PSTV) (PLUS OR THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDES AN OVERVIEW OF RECENT AND UPCOMING BUSINESS HIGHLIGHTS. THE SECOND QUARTER OF 2025 MARKED STEADY EXECUTION AND PROGRESS ON OUR KEY STRATEGIC INITIATIVES: CLINICAL DEVELOPMENT OF OUR RADIOTHERAPEUTIC AND THE ADVANCEMENT OF OUR DIAGNOSTIC PLATFORM TECHNOLOGIES TOWARD COMMERCIALIZATION, SAID MARC H.

PLUS THERAPEUTICS REPORTS SECOND QUARTER FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

CNSIDE CAN QUANTIFY LEPTOMENINGEAL METASTASES (LM) OVER TIME AND MONITOR CHANGES IN THE EXPRESSION OF MULTIPLE TARGETABLE MUTATIONS

PLUS THERAPEUTICS PRESENTS POSITIVE CNSIDE CSF ASSAY PLATFORM RESULTS AT THE2025 SNO/ASCO CNS METASTASES CONFERENCE

CNSIDE AVAILABLE FOR THE STATE OF TEXAS IN AUGUST 2025 INITIAL COMMERCIAL FOCUS ON NCI-DESIGNATED CANCER CENTERS AND LARGE PRIVATE HEALTHCARE SYSTEMS COMPANY WILL EXPAND TESTING SERVICES AND BROADEN REGIONAL AVAILABILITY OVER THE NEXT 12 MONTHS HOUSTON, JULY 31, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCES THAT ITS WHOLLY-OWNED SUBSIDIARY, CNSIDE DIAGNOSTICS, LLC (CNSIDE) WILL MAKE CNSIDE CEREBROSPINAL FLUID (CSF) ASSAY PLATFORM AND TESTING SERVICES COMMERCIALLY AVAILABLE IN TEXAS IN AUGUST 2025. INITIAL COMMERCIAL FOCUS WILL BE ON NATIONAL CANCER INSTITUTE (NCI) DESIGNATED CANCER CENTERS, WHICH TREAT THE HIGHEST NUMBER OF PATIENTS AT RISK FOR LEPTOMENINGEAL METASTASES (LM) AND PREVIOUSLY USED CNSIDE.

PLUS THERAPEUTICS PROVIDES US LAUNCH UPDATE FOR ITS CNSIDE DIAGNOSTIC

PAYMENT IS PART OF $17.6 MILLION AWARD GRANTED FOR LEPTOMENINGEAL CANCER TARGETED RADIOTHERAPEUTIC DEVELOPMENT PROGRAM PAYMENT IS PART OF $17.6 MILLION AWARD GRANTED FOR LEPTOMENINGEAL CANCER TARGETED RADIOTHERAPEUTIC DEVELOPMENT PROGRAM

PLUS THERAPEUTICS ANNOUNCES $1.6 MILLION ADVANCE PAYMENT FROM CPRIT

PRESENTATION BY TRIAL PRINCIPAL INVESTIGATOR AT THE 2025 SNO/ASCO CNS METASTASES CONFERENCE PLUS WILL ALSO HOST AN EDUCATIONAL SYMPOSIUM WITH LEADING EXPERTS TITLED, REIMAGINING YOUR APPROACH TO LEPTOMENINGEAL METASTASES HOUSTON, JULY 15, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCES THE ORAL PRESENTATION OF ITS RESPECT-LM CLINICAL TRIAL RESULTS AND A SPONSORED EDUCATIONAL SYMPOSIUM, AT THE UPCOMING SNO/ASCO CNS METASTASES CONFERENCE ON AUGUST 14-16, 2025, AT THE BALTIMORE WATERFRONT MARRIOTT HOTEL IN BALTIMORE, MD. PREVIOUSLY PRESENTED DATA FROM RESPECT-LM WAS HIGHLY ENCOURAGING IN BOTH THE SAFETY PROFILE AND RESPONSE SIGNAL IN PATIENTS WITH LEPTOMENINGEAL METASTASES OR LM, SAID MICHAEL ROSOL, PH.D.

PLUS THERAPEUTICS PRESENTS RESPECT-LM CLINICAL TRIAL RESULTS FOR REYOBIQ IN PATIENTS WITH LEPTOMENINGEAL METASTASES

THE JOINT SOCIETY FOR NEURO-ONCOLOGY (SNO) AND THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) FOCUS ON THE RAPIDLY EVOLVING AREA OF CENTRAL NERVOUS SYSTEM METASTASES

PLUS THERAPEUTICS ANNOUNCES TWO CNSIDE PRESENTATIONS AT THE UPCOMING SNO/ASCO CNS METASTASES CONFERENCE

SUBSTANTIAL CLINICAL NEED EXPECTED TO FACILITATE RAPID OVERALL TRIAL ENROLLMENT SUBSTANTIAL CLINICAL NEED EXPECTED TO FACILITATE RAPID OVERALL TRIAL ENROLLMENT

PLUS THERAPEUTICS ANNOUNCES INITIAL PATIENTS SUCCESSFULLY TREATED IN RESPECT-LM DOSE OPTIMIZATION TRIAL FOR REYOBIQ IN LEPTOMENINGEAL METASTASES

PRIMARY OBJECTIVE TO DETERMINE OPTIMAL DOSING SCHEDULE FOR A REGISTRATIONAL TRIAL TRIAL BUILDS ON RECOMMENDED PHASE 2 DOSE DETERMINED IN COMPLETED PHASE 1 TRIAL TRIAL BENEFITS FROM $17.6M AWARD FROM THE CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS HOUSTON, JUNE 30, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ: PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCES THE INITIATION OF THE RESPECT-LM DOSE OPTIMIZATION TRIAL FOR REYOBIQTM (RHENIUM RE186 OBISBEMEDA) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM). THE DOSE OPTIMIZATION TRIAL FOLLOWS ENCOURAGING RESULTS FROM THE COMPANY'S SINGLE-DOSE ESCALATION TRIAL AND IS DESIGNED TO EVALUATE MULTIPLE-DOSE REGIMENS OF REYOBIQ ADMINISTERED AT DEFINED INTERVALS VIA INTRAVENTRICULAR CATHETER (OMMAYA RESERVOIR).

PLUS THERAPEUTICS ANNOUNCES FDA AGREEMENT TO INITIATE RESPECT-LM DOSE OPTIMIZATION TRIAL FOR REYOBIQ IN LEPTOMENINGEAL METASTASES

U.S. COMMERCIAL ROLLOUT OF NOVEL DIAGNOSTIC PLATFORM TO BEGIN SECOND HALF 2025 UNDERSERVED CNS CANCER DIAGNOSTIC U.S. MARKET OPPORTUNITY ESTIMATED TO BE IN EXCESS OF $6 BILLION MANAGEMENT TO HOST A CONFERENCE CALL TODAY AT 9AM ET HOUSTON, JUNE 26, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, WILL PROVIDE A BUSINESS UPDATE FOR ITS WHOLLY-OWNED SUBSIDIARY, CNSIDE DIAGNOSTICS, LLC (CNSIDE). THE PROPRIETARY CNSIDE CEREBROSPINAL FLUID (CSF) ASSAY PLATFORM IS DESIGNED AND INTENDED FOR PATIENTS SUSPECTED OF HAVING CENTRAL NERVOUS SYSTEM CANCER METASTASES (CNS METS).

PLUS THERAPEUTICS PROVIDES BUSINESS UPDATE ON CNSIDE DIAGNOSTICS SUBSIDIARY

HOUSTON, JUNE 25, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCES THAT THE COMPANY WILL PROVIDE A BUSINESS UPDATE ON THURSDAY, JUNE 26, 2025 BEFORE THE MARKET OPEN. PLUS THERAPEUTICS' MANAGEMENT TEAM WILL THEN HOST A CONFERENCE CALL AND WEBCAST AT 9:00 A.M. ET TO DISCUSS AND PROVIDE ADDITIONAL DETAILS.

PLUS THERAPEUTICS TO PROVIDE BUSINESS UPDATE AND HOST CONFERENCE CALL ON THURSDAY, JUNE 26, 2025 AT 9:00 A.M. ET

COMPREHENSIVE RESTRUCTURING ELIMINATES THE POTENTIAL ISSUANCE OF UP TO 1.5 BILLION SHARES OF COMMON STOCK PLUS THERAPEUTICS FILES A REQUEST TO WITHDRAW THE RELATED RESALE REGISTRATION STATEMENT WITH THE SEC

Plus Therapeutics, Inc.

PSTV

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Plus Therapeutics, Inc.

PSTV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PSTV